Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 94.40B P/E 17.12 EPS this Y -45.20% Ern Qtrly Grth -
Income 485M Forward P/E 11.63 EPS next Y 90.70% 50D Avg Chg -2.00%
Sales 27.45B PEG 3.99 EPS past 5Y 1.66% 200D Avg Chg -6.00%
Dividend 4.00% Price/Book 4.50 EPS next 5Y 4.94% 52W High Chg -16.00%
Recommedations 2.50 Quick Ratio 0.82 Shares Outstanding 1.25B 52W Low Chg 25.00%
Insider Own 0.11% ROA 10.50% Shares Float 1.24B Beta 0.24
Inst Own 87.92% ROE 2.39% Shares Shorted/Prior 21.16M/22.57M Price 75.68
Gross Margin 77.52% Profit Margin 1.77% Avg. Volume 5,671,716 Target Price 74.61
Oper. Margin 34.43% Earnings Date Aug 8 Volume 5,249,684 Change 0.00%
About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc. News
05/20/24 Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
05/18/24 Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
05/14/24 Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
05/14/24 Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
05/13/24 One stock is dragging down the S&P 500's earnings growth
05/10/24 Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
05/09/24 Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
05/09/24 Gilead's FOCUS Program Helps Zero In on Early HIV Detection
05/09/24 Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
05/07/24 Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
05/07/24 Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
05/06/24 Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
05/04/24 23 Most Profitable Stocks of the Last 12 Months
05/03/24 Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
05/03/24 The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
05/02/24 Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
05/01/24 Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
04/30/24 Gilead Sciences to Present at Upcoming Investor Conferences
04/30/24 Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
04/29/24 Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD Chatroom

User Image pauldrew2006 Posted - 11 hours ago

$GILD Even the yield isn’t worth it. You can do better in a C.D. without the daily manipulation

User Image pauldrew2006 Posted - 11 hours ago

$GILD Almost a decade of stagnation. Never ever buy a stock that is completely institutional owned. They will never let it run and that includes management

User Image resume777 Posted - 14 hours ago

@GwilliamG and $GILD has a history of paying >$5B compared to $NVS M&A strategy of <$5B acquisitions. https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion

User Image GwilliamG Posted - 14 hours ago

@resume777 - I'd love to think that $NVS is still in play for this....but I think there are so many $GILD stars aligning that it makes too much sense for that portfolio.

User Image GwilliamG Posted - 14 hours ago

@BamaWriter - I would say that if a someone like $GILD or $NVS wanted to leverage Iomab-ACT as a way to enhance their CAR-T value....they would need to move fast....essentially be in negotiations now

User Image DueDiligence9601 Posted - 18 hours ago

$GTHX $GILD From the GILD first quarter report, including cash on hand. That took a hit with the recent CymaBay acquisition. "Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales... Non-GAAP diluted (loss) EPS was $(1.32) in the first quarter 2024, compared to $1.37 in the same period in 2023. The decrease was primarily driven by the charge related to the acquisition of CymaBay. As of March 31, 2024, Gilead had $4.7 billion of cash, cash equivalents and marketable debt securities, compared to $8.4 billion as of December 31, 2023. During the first quarter 2024, Gilead generated $2.2 billion in operating cash flow. During the first quarter 2024, Gilead paid dividends of $990 million and repurchased $400 million of common stock."

User Image Polip Posted - 18 hours ago

$IOVA $MRK $GILD $PFE who will win the bidding contest?

User Image 2030orbust Posted - 1 day ago

$GILD - if you want a beat up name in HealthCare/BioTech with a good div check this name out. All time trendline looks great. Bullish on the turnaround in 2025 🀝

User Image IslandThyme Posted - 2 days ago

$GILD please purchase ATNM and its pipeline soon before price goes up

User Image Reversalbuzz Posted - 2 days ago

$GILD getting to first target

User Image Stock_Titan Posted - 2 days ago

$GILD Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis https://www.stocktitan.net/news/GILD/investigational-seladelpar-demonstrates-significant-improvements-in-wrjfx9areik2.html

User Image wilno Posted - 3 days ago

$GILD building a new base before rally to 75 by eoy!

User Image DefenseMania Posted - 3 days ago

Keep an eye on these presentations πŸ˜‰ $GILD $AMGN $AZN $PFE https://finance.yahoo.com/news/arcus-biosciences-present-data-phase-200000387.html

User Image DefenseMania Posted - 3 days ago

$GILD $RCUS sounds like a partnership in the makings πŸ’°πŸ’°πŸ’°

User Image Apr4609 Posted - 3 days ago

$GILD $LPTX

User Image GwilliamG Posted - 4 days ago

$ATNM -- Reminder team -- the KOL call is 8AM EDT Monday morning. Gotta love the timing (for us MT and PT folks).....VERY pre-market Register here...https://lifescievents.com/event/actinium/ Got any predictions for the CAR-T partner? $NVS or $GILD

User Image wilno Posted - 4 days ago

$GILD 75 by eoy!

User Image 2030orbust Posted - 4 days ago

Adding more to $GILD once the additional funds hit tomorrow. Big reversal candle on 5/10. Todays candle looks to take out yesterdays bearish candle. Reversal confirmation underway.

User Image GwilliamG Posted - 4 days ago

@resume777 @TechGal -- gotta be $GILD --- I feel like $NVS had their shot at this last year.....and well, here we are....

User Image micknikolas Posted - 4 days ago

$GILD

User Image KongTrader1 Posted - 4 days ago

$TSOI $PFIZER.NSE $GILD $CELZ Great news today about phase 3 https://www.businesswire.com/news/home/20240516930973/en/Therapeutic-Solutions-International-Receives-Notice-of-Allowance-for-Landmark-Patent-Covering-Cellular-Therapy-of-Lung-Diseases

User Image Noobnr1 Posted - 4 days ago

$DVAX we need some triggers or an unexpected buyout πŸš€πŸš€πŸš€ $PFE $GILD

User Image DefenseMania Posted - 4 days ago

$ABBV fueling like a big biotech merger is brewing $AZN + $GILD ? $AMGN $PFE

User Image SearchFor911 Posted - 4 days ago

$ASMB no show at every investor conference. So they already have investors willingly to invest in a capital raise or there won't be any.... because of..... $GILD πŸš€

User Image DojiDaddy Posted - 5 days ago

$GILD

User Image DefenseMania Posted - 5 days ago

$RCUS 1hr before healthcare conference $PFE $GILD $AMGN $ABBV

User Image wilno Posted - 5 days ago

$GILD few more legs up and we hit 75 by eoy!

User Image Darkwatcher69 Posted - 6 days ago

$GILD 85!!! Coming in hot!

User Image GwilliamG Posted - 6 days ago

@Karmic @Hawaiianinvesta β€” is $GILD gonna be there? Hmmmm

User Image WallStArb Posted - 6 days ago

$ASMB interesting to see how this performs going into data into the fall - also curious if $GILD picks up any new indications by the fall

Analyst Ratings
Barclays Equal-Weight Apr 29, 24
TD Cowen Buy Apr 26, 24
Morgan Stanley Equal-Weight Apr 26, 24
RBC Capital Sector Perform Apr 26, 24
Needham Hold Apr 26, 24
HSBC Hold Apr 24, 24
Oppenheimer Outperform Apr 19, 24
UBS Neutral Apr 17, 24
Wells Fargo Equal-Weight Mar 4, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dickinson Andrew D Chief Financial Offi.. Chief Financial Officer Jan 16 Sell 85.78 5,000 428,900 101,534 01/17/24
Mercier Johanna Chief Commercial Off.. Chief Commercial Officer Jan 09 Sell 85.23 8,242 702,466 82,729 01/10/24
Parsey Merdad Chief Medical Office.. Chief Medical Officer Sep 12 Sell 76.99 1,501 115,562 70,130 09/13/23
Dickinson Andrew D Chief Financial Offi.. Chief Financial Officer Jul 20 Sell 80.00 5,000 400,000 107,587 07/21/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Jun 13 Sell 76.90 1,485 114,197 29,402 06/14/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Mar 13 Sell 78.99 6,126 483,893 70,130 03/14/23
Lofton Kevin E Director Director Mar 09 Option 52.38 8,442 442,192 8,442 03/10/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Mar 01 Sell 79.9619 12,984 1,038,225 70,130 03/02/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Dec 30 Sell 85.33 553 47,187 45,556 01/03/23
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Nov 01 Option 72.7 16,255 1,181,738 44,588 11/02/22
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Nov 01 Sell 79.25 16,255 1,288,209 28,333 11/02/22
Lofton Kevin E Director Director Apr 28 Option 25.625 16,322 418,251 90,525 04/29/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Mar 10 Sell 58.24 3,634 211,644 32,576 03/14/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Feb 09 Sell 63.89 1,691 108,038 32,576 02/11/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Feb 01 Sell 68.5358 14,061 963,682 32,576 02/02/22
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Aug 18 Sell 72.5 13,610 986,725 20,398 08/18/21
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Aug 18 Option 67.56 13,610 919,492 34,008 08/18/21
Whitley Richard James Director Director May 04 Option 20.65 20,282 418,823 51,404 05/04/21